David Kallend
Impact in
-
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Surgery top 0.2%
- Lipoproteins and Cardiovascular Health
- Cholesterol and Lipid Metabolism
Papers in
- Surgery 59
- Lipoproteins and Cardiovascular Health 54
- Cholesterol and Lipid Metabolism 7
-
- Diabetes, Cardiovascular Risks, and Lipoproteins 10
- Co-authors
- Lawrence A. Leiter (36 shared papers)R. Scott Wright (22 shared papers)Peter Wijngaard (29 shared papers)John J.P. Kastelein (31 shared papers)Kausik K. Ray (34 shared papers)Wolfgang Köenig (22 shared papers)Frederick J. Raal (28 shared papers)Mark Jaros (10 shared papers)
- Journals
- Atherosclerosis (11 papers)Journal of the American College of Cardiology (11 papers)European Heart Journal (8 papers)Circulation (7 papers)Atherosclerosis Supplements (7 papers)
- Partner nations
- United StatesUnited KingdomNetherlands
In The Last Decade
David Kallend
95 papers receiving 7.8k citations
David Kallend's Hit Papers
Peers
Comparison fields: 5 of 110
- Endocrinology, Diabetes and Metabolism 1.9k
- Surgery 4.6k
- Cancer Research 1.2k
- Cardiology and Cardiovascular Medicine 1.4k
- Immunology 687
Countries citing papers authored by David Kallend
This map shows the geographic impact of David Kallend's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Kallend with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Kallend more than expected).
Fields of papers citing papers by David Kallend
This network shows the impact of papers produced by David Kallend. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Kallend. The network helps show where David Kallend may publish in the future.
Co-authors
The 25 scholars most cited alongside David Kallend, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 100 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome Hit paper breakdown → | 2012 | 1487 |
| 2 | Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol Hit paper breakdown → | 2020 | 1052 |
| 3 | Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol Hit paper breakdown → | 2017 | 751 |
| 4 | A Highly Durable RNAi Therapeutic Inhibitor of PCSK9 Hit paper breakdown → | 2016 | 600 |
| 5 | Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia Hit paper breakdown → | 2020 | 585 |
| 6 | Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial Hit paper breakdown → | 2011 | 379 |
| 7 | 2015 | 197 | |
| 8 | 2012 | 168 | |
| 9 | Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis Hit paper breakdown → | 2021 | 165 |
| 10 | 2009 | 140 | |
| 11 | Inclisiran and cardiovascular events: a patient-level analysis of phase III trials Hit paper breakdown → | 2022 | 138 |
| 12 | 2004 | 135 | |
| 13 | 2018 | 135 | |
| 14 | 2019 | 131 | |
| 15 | 2018 | 124 | |
| 16 | 2019 | 111 | |
| 17 | 2009 | 104 | |
| 18 | 2004 | 95 | |
| 19 | 2018 | 88 | |
| 20 | 2010 | 83 |
About David Kallend
David Kallend is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism, Cancer Research, Molecular Biology and Cardiology and Cardiovascular Medicine, having authored 100 papers that have together received 8.0k indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (54 papers), Cancer, Lipids, and Metabolism (11 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (10 papers), Computational Drug Discovery Methods (8 papers), Cholesterol and Lipid Metabolism (7 papers), Pharmaceutical Economics and Policy (7 papers), Cerebrovascular and Carotid Artery Diseases (5 papers) and RNA Interference and Gene Delivery (4 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (1.9k citations), Surgery (4.6k citations), Cancer Research (1.2k citations), Cardiology and Cardiovascular Medicine (1.4k citations) and Immunology (687 citations). David Kallend has collaborated with scholars based in United States, United Kingdom and Netherlands. Frequent co-authors include Lawrence A. Leiter, R. Scott Wright, Peter Wijngaard, John J.P. Kastelein, Kausik K. Ray, Wolfgang Köenig, Frederick J. Raal, Mark Jaros, Gregory G. Schwartz and Markus Abt. Their work appears in journals such as Atherosclerosis, Journal of the American College of Cardiology, European Heart Journal, Circulation and Atherosclerosis Supplements.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.